Why Is There No Cure for Herpes?

Herpes simplex virus (HSV) affects billions globally, with HSV-1 causing oral herpes and HSV-2 primarily responsible for genital infections. Despite effective antiviral treatments, there is still no cure, largely due to the virus’s ability to hide in nerve cells and evade elimination.

Antiviral drugs help manage symptoms and reduce transmission but cannot remove the virus from the body once infection is established.

Why herpes is so difficult to treat

After infecting the skin or mucous membranes, HSV travels along nerve fibers to sensory ganglia, where it enters a dormant state called latency. In this state, the viral DNA remains in the neuron’s nucleus as a circular episome, producing very few viral proteins.

This limited viral activity means the immune system cannot detect or attack the virus effectively. Neurons also have a specialized immune environment that minimizes inflammation, protecting both the nerve cells and the virus.

Because the virus is inactive and hidden in neurons, current antiviral drugs, which target replicating virus, cannot reach or eliminate latent HSV.

Herpes avoids the immune system and stays dormant for life

HSV uses multiple strategies to maintain latency and avoid immune detection. It modifies its DNA packaging to silence most viral genes and produces microRNAs that block viral replication.

The virus also disrupts the host’s antigen presentation, preventing immune cells from recognizing infected neurons. This stealth mode allows HSV to persist lifelong and reactivate periodically under triggers like stress or illness.

Antiviral medications such as acyclovir and valacyclovir inhibit viral DNA replication during active outbreaks, reducing symptoms and contagiousness. However, these drugs require the virus to be actively replicating to work.

During latency, the virus does not replicate or produce the proteins targeted by these drugs, so it remains untouched. Delivering treatments that can reach and safely eliminate latent virus in neurons remains a major scientific hurdle.

As a result, herpes management focuses on controlling outbreaks and transmission rather than curing the infection.

What progress has been made in developing herpes vaccines?

Vaccine development for HSV has been challenging, and the field saw a major setback when GSK discontinued its protein-subunit HSV-2 vaccine candidate in September 2024 after it failed to meet efficacy targets in Phase 2 trials, despite generating good antibody responses. This has pushed research further toward mRNA and live-attenuated platforms, which better stimulate the cellular immunity needed to control a latent virus.

Moderna's therapeutic mRNA-1608 and BioNTech's preventive BNT163 remain the leading mRNA candidates, both still in Phase 1/2 trials as of 2026, with interim data showing good tolerability and immune responses but no confirmed efficacy yet. Therapeutic vaccines like RVx201 from Rational Vaccines aim to strengthen the immune system's ability to control the virus in infected individuals, potentially reducing outbreak frequency and severity.

Despite these advances, no vaccine has yet been approved for widespread use, largely due to HSV's complex immune evasion strategies and the difficulty in generating strong, durable mucosal immunity. See our detailed 2027 vaccine candidate tracker for the latest trial statuses.

Gene editing could remove the hidden virus, but not yet in people

Gene editing technologies such as CRISPR and engineered meganucleases offer a promising new approach by directly targeting and disabling latent HSV DNA within nerve cells.

Preclinical studies, including those from Fred Hutchinson Cancer Center, have demonstrated over 90% reduction in viral DNA in animal models, indicating potential for a functional cure.

Unfortunately, challenges remain in safely delivering gene editors to neurons, avoiding off-target effects, and ensuring long-term safety before human clinical trials can begin.

New antivirals are closer to patients than any cure

Besides gene editing and vaccines, novel antiviral agents are being developed to improve herpes management. Gilead licensed Assembly Biosciences' long-acting helicase-primase inhibitors in December 2025 after Phase 1b trials cut viral shedding by up to 98% with a once-weekly pill. Gilead's GS-1179 (formerly ABI-1179) is expected to start Phase 2 by the end of 2026.

Pritelivir, a daily helicase-primase inhibitor from AiCuris, is under FDA Priority Review for drug-resistant herpes in immunocompromised patients, with a decision expected in late 2026. It would be the first new herpes drug in over 20 years.

Combining antivirals with immune modulators or gene editing tools may enhance treatment effectiveness by attacking the virus on multiple fronts.

Advances in personalized medicine and diagnostics could also help tailor therapies to individual patients, optimizing outcomes.

Why a cure for herpes is still a long-term goal

The main barrier to curing herpes is the virus’s ability to remain dormant and hidden in nerve cells, inaccessible to current treatments. The biological complexity requires innovative approaches that can safely target latent virus without damaging neurons.

While promising technologies like gene editing and vaccines are advancing, extensive research, funding, and clinical trials are still needed to bring a cure to patients.

Research is moving faster than at any point in the last 20 years

Scientific progress in understanding HSV biology, immune evasion, and latency has accelerated in recent years, fueling optimism for new therapies that could one day cure herpes.

With ongoing research in vaccines, gene editing, and novel antivirals, the goal of eliminating HSV infection is becoming more achievable, offering hope to millions worldwide living with herpes.